VN February 2024

Vetnuus | Februarie 2024 20 « BACK TO CONTENTS to erythromycin, lincosamides (such as clindamycin), or certain β-lactams (such as dicloxacillin or cephalexin), so these antibiotics are not recommended as monovalent treatments for animal bites. Instead, a combination of amoxicillin and the β-lactamase inhibitor clavulanic acid (Augmentin), doxycycline plus metronidazole for patients with penicillin allergies, or clindamycin plus a fluoroquinolone (ciprofloxacin, or trimethoprim-sulfamethoxazole combination for children or ceftriaxone for pregnant women) is the recommended treatment regimen (41, 48, 309). Vaccination The relatively low incidence of human pasteurellosis, despite the high prevalence of Pasteurella species in domestic and wild animals, supports the premise that Pasteurella is an opportunistic pathogen for humans. Further support for this comes from studies examining the carriage and anti-Pasteurella antibody levels in individuals with occupational or other extensive exposure to animals (85, 152). Because of the relatively low incidence of human infection, most immunization or vaccination studies against Pasteurella infection have been geared toward controlling animal disease. Despite considerable effort and ample experimental animal models, mechanisms of protective immunity against Pasteurella remain elusive, and so development and evaluation of effective vaccines have been challenging (34, 449, 538). Detection of high serum levels of IgG antibodies is not indicative of clearance of or resistance to Pasteurella infection but rather is indicative of chronic infection (178, 475, 539, 540). Vaccination using toxin-based component vaccines, bacterins, or live attenuated bacteria is effective against toxin-mediated disease, such as atrophic rhinitis (449, 471, 541–552). A commercial swine vaccine based on P. multocida bacterin-toxoid (BT) conferred protective immunity in rabbits against PMT challenge (553). To prevent vertical transmission of P. multocida from sows to suckling pigs or laterally among young weaned animals, sows are often vaccinated once or twice prior to farrowing to induce passive immunity through colostrum (542, 554–557). However, despite the benefits of PMT-based vaccination for prevention of atrophic rhinitis and other disease symptoms in swine and rabbits (543, 544, 553, 555, 557–559), current commercial and experimental vaccines do not confer complete immunity to P. multocida infection and are not effective in clearing the bacteria (542, 551, 555). Although PMT activates dendritic cells, it is a poor adjuvant and appears to suppress the antibody response in vivo (497). PMT is nonetheless an effective immunogen, and mutant derivatives have shown potential for vaccine development against atrophic rhinitis (543, 544, 549–551, 555, 557, 560, 561). Several of the Pasteurella outer membrane proteins are putative virulence factors and potential targets for vaccine development (reviewed in reference 433). For example, antisera against the outer membrane protein Oma87 protected mice against a lethaldose challenge of P. multocida (447). Vaccination with recombinant adhesion protein Cp39 from P. multocida strain P-1059 protected chickens from challenge with strain P-1059 (serotype A:3) and strain X-73 (serotype A:1) (436, 448). OmpH-specific antibodies were more effective than OmpA-specific antibodies in curbing P. multocida growth in mice, presumably by enhancing PMN phagocytosis (562). Full-length OmpH was more effective than shorter fragments as a vaccine against a swine strain of P. multocida (isolated from a case of atrophic rhinitis) in a mouse challenge model (563). Although OmpA elicits a strong antibody response, vaccination is not protective in a mouse model of infection (435). The type 4 fimbrial subunit of serotype A, B, and D strains has been identified as a potential vaccine candidate (439, 449); however, efficacy as a vaccine has been reported only for the fimbrial protein from serotype B:2 against hemorrhagic septicemia in goats (564). Using a bioinformatics approach, 98 genes in avian strain Pm70 and 107 genes in the nontoxinogenic porcine strain 3480 were identified as encoding putative OMPs (415). Of this combined list, 71 recombinant proteins were expressed and purified, albeit most as insoluble proteins, and tested as vaccine candidates. Only one protein, lipoprotein E (PlpE), was found to protect against P. multocida challenge in chickens and mice, which confirmed previously reported results using the PlpE cloned from the avian serotype A:1 strain X-73 (446). However, a plpE knockout mutant strain retained full virulence (416). Conjugated vaccines comprised of multiple antigens, such as OmpH plus PlpE peptides, have also shown promise (445, 565). Additional vaccine candidates include the filamentous hemagglutinin protein (FhaB2) (566), iron-regulated Omps (567–570), and LPS (109). Vaccination with peptides derived from FhaB2 protected turkeys from fowl cholera upon challenge with P. multocida P1059 (566). LPS is a major virulence factor and immunogen of P. multocida, but its potential use and efficacy as a vaccine candidate is complicated by the structural heterogeneity of the 16 different serovars (109). Several in vivo-expressed surface antigens have been identified as potential vaccine candidates (72, 538, 571). A number of these are iron-regulated Omps expressed during P. multocida infection and have been characterized as potential immunogens in challenge studies (568–573). For example, the 96-kDa heme acquisition system receptor (HasR) protein is a surface-exposed Omp conserved among most P. multocida isolates. HasR is expressed under low-iron conditions in vivo and confers protection against challenge with bovine P. multocida serotype A:3 strain 232 (568). A whole-cell vaccine based on a serotype A:1 strain of P. multocida that has been inactivated by treatment with high iron concentrations has also been explored (574). A few bacterin- and/or toxin-based vaccines are available commercially. For example, Porcillis AR-T DF is a PMT-based vaccine comprised of a deletion mutant of PMT (Δ28-148) plus inactivated Bordetella bronchiseptica bacterin. A commercial vaccine against fowl cholera (chickens and turkeys), sold as CholeramuneM, Multimunem, or M-Ninevax-C, is available and is based on a freezedried preparation of a live, avirulent avian isolate of P. multocida M-9 strain (a serotype A:3-A:4 cross). A trivalent combination vaccine against fowl cholera (for ducks, chickens, and other poultry) and rabbit pasteurellosis, sold as Landavax, is available as an inactivated bacterin oil emulsion of P. multocida serotype A:1, A:3, and A:4 strains. A tetravalent combination vaccine, sold as Rhini ShieldTX4, provides four-way protection against swine PMT-mediated atrophic rhinitis and respiratory diseases through a bacterin containing inactivated B. bronchiseptica, Erysipelothrix rhusiopathiae (the causative agent Leading Article (Pasteurella multocida)

RkJQdWJsaXNoZXIy OTc5MDU=